Salud financiera de hoja de balance de Cellectar Biosciences

Salud financiera controles de criterios 5/6

Cellectar Biosciences tiene un patrimonio de los accionistas total de $26.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $42.9M y $16.7M respectivamente.

Información clave

Ratio deuda-patrimonio

US$0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	US$40.03m
Patrimonio	US$26.17m
Total pasivo	US$16.74m
Activos totales	US$42.91m

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

May 10

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Jan 20

Recent updates

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Jun 04

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20

Cellectar Biosciences EPS beats by $0.03

May 10

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Apr 27

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Jan 12

Cellectar Bio readies stock offering

Dec 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30

Cellectar Biosciences EPS beats by $0.05

Nov 09

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Nov 05

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($41.4M) de CLRB superan a sus pasivos a corto plazo ($16.3M).

Pasivo a largo plazo: Los activos a corto plazo de CLRB ($41.4M) superan a sus pasivos a largo plazo ($474.3K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: CLRB está libre de deudas.

Reducción de la deuda: CLRB no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: CLRB tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: CLRB tiene menos de un año de cash runway si el flujo de caja libre sigue reduciéndose a tasas históricas de 22% cada año

Salud financiera de hoja de balance de Cellectar Biosciences

Salud financiera controles de criterios 5/6

Información clave

Actualizaciones recientes sobre salud financiera

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Recent updates

Cellectar Biosciences, Inc. to Report Q1, 2024 Results on May 14, 2024

Cellectar Biosciences, Inc., Annual General Meeting, Jun 14, 2024

New minor risk - Market cap size

New major risk - Financial position

Price target increased by 23% to US$14.75

Cellectar Biosciences, Inc. to Report Fiscal Year 2023 Results on Mar 27, 2024

Cellectar Biosciences, Inc. Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

New major risk - Shareholder dilution

Cellectar Biosciences, Inc. Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1B Clinical Study

Cellectar Biosciences, Inc. Reports Complete Central Nervous System (CNS) Clearance in Relapsed/Refractory Waldenstrom’s Macroglobulinemia Patient

Forecast to breakeven in 2026

Cellectar Biosciences Broadens Pipeline with Targeted Alpha Therapy for Solid Tumors and Releases Promising Preclinical Data

Cellectar Biosciences Announces Positive Topline Data Achieving Primary Endpoint in Pivotal Clinical Study of Iopofosine I 131 in Waldenstrom's Macroglobulinemia

Forecast to breakeven in 2026

New minor risk - Profitability

Cellectar Biosciences, Inc. announced that it has received $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc.

Nasdaq Grants Cellectar Biosciences an Extension to Take Action to Evidence Compliance with Nasdaq Listing Rule 5550(b), on or Before January 4, 2024

Cellectar Biosciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Cellectar Biosciences, Inc. Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom's Macroglobulinemia

Price target decreased by 7.7% to US$12.00

Cellectar Biosciences, Inc. announced that it expects to receive $102.9 million in funding from Aigh Capital Management, LLC, ADAR1 Capital Management, LLC, Second Line Capital, LLC, Nantahala Capital Management, LLC, AuGC Partners LLC, Rosalind Advisors, Inc. and other investors

Cellectar Biosciences Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Stockholders’ Equity Requirement Pursuant to Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

New minor risk - Share price stability

Cellectar Biosciences, Inc. Provides an Update for Its iopofosine I 131 Clinical Program and Guidance Related to Its Proprietary Phospholipidether Drug Conjugate Platform

Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical

Cellectar Biosciences, Inc. Announces Appointment of Shane Lea as Chief Commercial Officer

Cellectar Biosciences, Inc. Announces Presentation of Data on CLR 12120 Series of Targeted Alpha-Emitting Therapies at the 13th Annual World ADC Conference

Cellectar Biosciences, Inc. Announces Resolution of Breach of Contract and Intellectual Property Dispute

Price target decreased to US$12.60

Price target decreased to US$33.63

Cellectar Biosciences, Inc. announced that it has received $3.911327 million in funding

Cellectar Biosciences, Inc. Wins $2 Million Grant to Expand Its Ongoing Phase 1 Study of Iopofosine I 131 in Pediatric Brain Tumors

Cellectar Biosciences, Inc. Announces Publication of Data from its Expansion Cohort of the Phase II CLOVER-1 Study Iopofosine I-131 in Relapsed/Refractory Multiple Myeloma in Nature’s Blood Cancer Journal

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Price target decreased to US$39.38

Cellectar announces reverse stock split

Price target increased to US$5.88

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nasdaq Grants Extension to Cellectar Biosciences Until October 31, 2022 to Regain Compliance

Cellectar Biosciences, Inc., Annual General Meeting, Jun 15, 2022

Cellectar Biosciences Appoints Jarrod Longcor as Chief Operating Officer

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Cellectar Biosciences, Inc. Presents Data from Its Ongoing Phase 2 Clover-1 Study of Iopofosine I-131 At the 63rd Ash Annual Meeting and Exposition

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar Biosciences, Inc. Announces the Completion of the Part A Portion of A Safety and Tolerability Study of Iopofosine I-131 (Iopofosine) in Combination with External Beam Radiation (Ebrt) in Relapsed or Refractory Head and Neck Cancer

Price target decreased to US$5.38

High number of new directors

Cellectar Presents Data in Waldenstrom’s Macroglobulinemia in Poster At the 2021 American Society of Clinical Oncology Annual Meeting

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

Cellectar Biosciences, Inc. Receives Notification of Formal Grant of the Patent Titled Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles by the Eurasian, Australian and Mexican Patent Authorities

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Cellectar Biosciences, Inc. Announces Japan Patent Office Granted Patent, Titled, 'Phospholipid-Ether Analogs as Cancer-Targeting Drug Vehicles'

New 90-day low: US$1.74

Cellectar Biosciences, Inc. Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Cellectar Biosciences, Inc. announced that it has received $20.5065 million in funding

Cellectar Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $24.499984 million.

Cellectar Biosciences, Inc. announced that it expects to receive $20.5 million in funding

Cellectar Bio readies stock offering

New 90-day high: US$2.66

New 90-day high: US$1.52

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Cellectar Biosciences EPS beats by $0.05

Cellectar Biosciences, Inc. Announces CLR 131 Has Demonstrated Preliminary Activity in Inoperable Brain Tumors in Phase 1 Study